Specialty Oncology Biotherapeutics
-
You must log in to register
- Nonmember - $350
- Full Member - $225
- Associate Member - $225
- Emeritus Member - $225
- Government Associate Member - $225
- Government Full Member - $225
- Postdoctoral Researcher/Transitional Member - $125
- Student Member - $125
To further its mission to educate, lead, and serve, the American College of Toxicology is proud to offer an eLearning Seminar focused on Specialty Oncology Biotherapeutics. These four modules are intended to present practical, real-world nonclinical, regulatory, and in vivo study considerations for the development of specialty oncology biotherapeutics, including cell therapies, complex protein biotherapeutics, including immunomodulatory molecules, and oncolytic viruses.
Modules will be available for purchase as a discounted set of four modules only. Once the live module presentations conclude, registrants will have on-demand access to the modules for 30 days from the time each archive is first accessed. Each module is 90 minutes or fewer in duration.
Disclaimer:
This seminar reflects the views of the speaker and should not be construed to represent the views or policies of the American College of Toxicology. Examples presented in this seminar may have required unique strategies that do not necessarily apply to other modalities or situations. Regulatory guidelines and best practices are constantly evolving, and the viewer is encouraged to independently confirm their understanding with what was presented in this seminar.
-
Contains 3 Component(s) Recorded On: 05/04/2023
Oncology Series
There is more than one regulatory guideline that needs to be taken into consideration depending on the therapeutic modality of a biotherapeutic being developed for oncology indications. Protein-based biotherapeutics generally fall under one set of regulatory guidelines, while cell and gene therapy products fall under a different set. There are several key differences in the regulatory requirements for oncology versus nononcology indications, biotherapeutics versus small molecules, and protein biotherapeutics vs cell and gene therapies. This presentation will give an overview of the primary regulatory guidelines for the different modalities as well as highlight the similarities and differences in approaches to developing a nonclinical strategy to fulfill regulatory expectations for each type of modality. In the last few years, non-human primates (NHPs) have been in high demand, and a critical shortage of animals has developed worldwide. Considerations around the use of non-human primates (NHPs) will be discussed including: 1) if certain types NHP studies are always needed; 2) strategies that include not conducting toxicity studies in NHPs if rodents are pharmacologically relevant, and development programs where there are no pharmacologically relevant species, including NHPs.
$i++ ?>Marque Todd, DVM, DABT
Consultant
Renaissance Consulting
Dr. Marque Todd is a board-certified regulatory toxicology expert. Dr. Todd trained as a veterinarian and completed post-doctoral work in molecular immunology and cancer biology. She has more than 25 years of experience working in the biopharmaceutical industry. Dr. Todd has extensive nonclinical development experience with a variety of biologic modalities including monoclonal antibodies, bi-specific antibodies, Fc and other fusion proteins, antibody-drug conjugates, cytokines/interleukins, protein replacement therapies, nanoparticles, cell therapies, oncolytic viruses, and therapeutic vaccines. Dr. Todd has been involved in the preparation and submission of nonclinical sections of early and late-stage regulatory documents including INDs and BLAs/NDAs and has participated in numerous successful health authority meetings.
Dr. Todd is currently a regulatory toxicology consultant to several large, mid-size and small biopharma companies. Prior to becoming an independent consultant, Dr. Todd was a Research Fellow at Pfizer and served as a Principal Scientist at Amgen and Chiron. Dr. Todd also served as an Adjunct Professor with the University of California San Diego Extension, where she co-taught a course on nonclinical toxicology and drug development with sessions focused on the nonclinical development of biotherapeutics and oncology products.
-
Contains 3 Component(s) Recorded On: 03/16/2023
Oncology Series
There has been a rapid growth of cell therapy approaches over the past several years, resulting in product approvals providing substantial advancements in the treatments of serious diseases particularly in oncology. Cell-based therapies are the transfer of intact, live cells into a patient with the goal of preventing, treating, or curing a disease or condition. The source of the cells may come from the patient who will also be the recipient, in which case the source is termed autologous, or the cells may be obtained from a donor, in which case the source is termed allogeneic. These cells may be modified through gene-editing, treatment with cytokines, and/or other novel techniques. Generally, cell therapies use case-by-case approaches as they advance through the product development and regulatory interactions to the clinic, and eventually the marketplace. This session will address the overarching nonclinical challenges as well the more practical challenges of program and study execution. In addition, how interactions with regulators can help address these challenges will be discussed.
$i++ ?>Mary Ellen Cosenza, PhD, MS, DABT, ATS, ERT, RAC
Consultant
MEC Regulatory and Toxicology Consulting
Dr. Mary Ellen Cosenza is a regulatory consultant with over 30 years of senior leadership experience in the biopharmaceutical industry in the US, Europe, and emerging markets. During her 20-year tenure at Amgen, she led the US Regulatory Department, the International Emerging Markets Regulatory Department, and served as an Executive Director of Global Regulatory Affairs and Safety, focusing on Early Development, Medical Writing, and Inflammation. In addition to her leadership roles in Regulatory Affairs, she also served as the Senior Director of Toxicology at Amgen. Prior to joining Amgen, she served as a Principal Scientist in Toxicology for the Medical Research Division of American Cyanamid Company (now Pfizer).
While at Amgen, Dr. Cosenza was responsible for both early- and late-stage development programs resulting in numerous successful IND, CTA, NDA, MAA, and BLA submissions in a wide variety of therapeutic areas and modalities. In addition, she played a key leadership role in preparing teams for global health authority meetings with FDA, EMA, and regional country health authorities, including several FDA Advisory Committee Meetings.
Dr. Cosenza is recognized as an expert in preclinical biologic drug development and is a founding member of BIO’s BioSafe Preclinical Expert group. She was also a member of an Expert Working Group, operating under the auspices of the International Conference on Harmonization (ICH) for ICH M3(R2). Dr. Cosenza is well-published in the field of biological drug development, has authored several chapters on this topic, and recently co-edited a book on Translation Sciences focused on biologics and innovative products such as cell and gene therapies. She was also a co-editor of a Toxicological Pathology book for non-pathologists.
Dr. Cosenza is a Diplomat of the American Board of Toxicology, a Fellow of the Academy of Toxicological Sciences (current President), a member of the Society of Toxicology (SOT), Drug Information Association (DIA), and the Regulatory Affairs Professional Society (RAPS), and holds Regulatory Affairs Certification for both the US and EU. Dr. Cosenza is a European Registered Toxicologist (ERT) via the Royal Society of Biology, UK. She is also Treasurer of the International Union of Toxicology (IUTOX). Dr. Cosenza is a member of the American College of Toxicology (ACT), where she has served as a member of the ACT Education Committee, as Councilor, and as Treasurer and then President. She is an adjunct at the University of Southern California, where she teaches a graduate-level course on Food and Drug Toxicology and undergraduate classes on drug development and toxicology.
Dr. Cosenza received her PhD from St. John’s University, New York, and her MS in Regulatory Science from the University of Southern California, Los Angeles.
-
Contains 3 Component(s) Recorded On: 05/04/2023
Oncology Series
Part 1: Immune Assessment of Immunomodulatory Biotherapeutics
In Part 1 of this module, we will review both in vitro and in vivo models to characterize the immunopharmacology and assess the safety risks of immunomodulatory biotherapeutics. The mechanisms of cytokine release, immune cell activation/modulation, antibody-dependent cell cytotoxicity (ADCC), antibody-dependent cell phagocytosis (ADCP), complement-dependent cytotoxicity (CDC), and other immunological activities will be reviewed. The use of in vitro assays to assess these activities, as well as in vivo animal models incorporating blood and tissue immune cell immunophenotyping by flow cytometry, quantification of cytokines/chemokines, complement components, and acute phase reactants, and assessing immune function endpoints to characterize these immunological activities of biotherapeutics will be discussed. The requirement for such assays and key considerations for study design (e.g., for cytokine release assays (CRAs), whether PBMCs or whole blood, or soluble or immobilized drug should be used) will be discussed, and decision trees, based on drug structure, mechanism of action, and other risk factors, will be reviewed. Gaps in translation of these models to humans will be discussed, and suggestions to fill these gaps proposed. How these immunopharmacology/immunosafety data are considered with other data in the selection of a First-In-Human starting dose and in clinical risk mitigation and risk management will also be considered in the context of short case studies.
Part 2: Approaches to MABEL Starting Dose Selection
Dose selection for first-in-human clinical trials with immune agonist biologics should be based on thoughtfully designed nonclinical pharmacology and toxicology studies, ex vivo/in vitro studies with human and animal cells, and pharmacokinetic/pharmacodynamic (PK/PD) modeling approaches. This approach requires a thorough understanding of the biology of the target and the relative binding and pharmacological activity of the molecule in animals and humans. Due to severe adverse events observed with Tegenero (an anti-CD28 superagonist mAb (TGN1412)) in 2006, choosing a safe starting dose and dose escalation for human trials with immune agonist biologics has been a focus of biotech companies as well as worldwide health authorities. With the increase in immune-oncology target identification and drug development in recent years, it is important to understand MABEL and the integrated data approach to setting the clinical starting dose. This presentation will discuss the importance of designing appropriate nonclinical pharmacology and toxicology studies, as well as ex vivo/in vitro studies with human and animal cells, to enable effective pharmacokinetic/ pharmacodynamic (PK/PD) modeling and clinical starting dose selection. Examples of successful starting dose approaches using a MABEL approach will also be presented.
$i++ ?>Sanela Bilic, PharmD, MBA
Senior Director of Clinical Pharmacology
D3 Medicine
Dr. Sanela Bilic is a highly respected professional with proven leadership skills and 18 years of broad experience within pharmaceutical drug development. She has extensive hands-on experience with all phases of drug development globally. Dr. Bilic possesses broad knowledge of drug development principles and practice ranging from target identification to early proof of concept, to tox interrogation, to IND, to early clinical development, and to mature development of small and large molecules. She is especially focused on the development of immuno-oncology therapeutics and ADCs. Dr. Bilic has also guided teams through the development of CAR T-cell, armed T-cell, and NK-cell therapies. In addition, she has extensive regulatory interaction experience with all major global health authorities.
After obtaining a Doctorate in Pharmacy and an MBA, Dr. Bilic completed a 2-year fellowship in Drug Development from SUNY at Buffalo and Novartis Pharmaceuticals in Oncology. She started her professional life in the Oncology clinical pharmacology department at Novartis. Following Dr. Bilic’s exponential professional as well as personal growth with Novartis, she joined D3 Medicine (now Certara) as a Senior Director, Clinical Pharmacology. During her years at Novartis and Certara (D3 Medicine), Dr. Bilic was an integral part of the development team with extensive experience as the clinical pharmacology representative for global regulatory authority interactions. Dr. Bilic has worked as a clinical pharmacology leader between research and early development, early development, and late development, and has led due diligence efforts from a clinical pharmacology perspective to aid in thorough assessment of business development opportunities. Dr. Bilic has led the clinical pharmacology strategic development of numerous assets from preclinical development/research stage to the end of Phase 2 and beyond. She uses a unique problem-solving approach, applied in Pharma and with global regulatory agencies (FDA, EMEA, PMDA), resulting in a high rate of successful solutions. She has a track record of anticipating problems and resolving them early and is responsible for nonclinical and/or clinical PK sections of over 50+ pre-INDs, INDs, and IMPDs.$i++ ?>Frank Brennan, PhD
Executive Director of Preclinical Safety
Novartis Institutes for Biomedical Research
Dr. Frank Brennan is currently an Executive Director in the Department of Preclinical Safety (PCS) at the Novartis Institutes for Biomedical Research in Cambridge, Massachusetts (but working from his UK home). Dr. Brennan works across the Novartis Biologics Portfolio, with a focus on ImmunoOncology. He has over 30 years’ experience in immunology, immunotoxicology, immunogenicity, and safety assessment of biologics in academia, the CRO Industry (HLS, now Labcorp, UK), small biotechnology companies, mid-size Pharma (Novo Nordisk, UCB), and large Pharma (AstraZeneca and Novartis). This work has led to over 75 publications in peer-reviewed journals and books. Dr. Brennan is a former Chair of the Biotechnology Innovation Organization (BIOsafe) Leadership Committee and is currently an active member of several external industry and academic initiatives and consortia. Dr. Brennan has a Bachelor of Science Degree in Immunology from the University of Glasgow (Scotland), a PhD in Immunology and Microbiology from the University of Edinburgh (Scotland), and held a Postdoctoral position in Immunology/Rheumatology at Rush Medical Center in Chicago.
-
Contains 3 Component(s) Recorded On: 05/22/2023
Oncology Series
Part 1: Case Studies for the Development of Specialty Biotherapeutics–Oncolytic Virus Practical Considerations for Nonclinical Development and Case Study
Oncolytic viruses represent an important emerging class of anticancer agents. Historically, viruses were used to treat cancer beginning over 100 years ago. The evolution of oncolytic viruses has advanced to genetically engineered viruses designed to have enhanced tumor selectivity and, more recently, to “armed” oncolytic viruses encoding transgenes intended to improve selectivity or immune stimulation. Significant advances include the milestone first approval of an oncolytic virus to treat cancer with the FDA approval of talimogene laherparepvec (T Vec), an engineered herpes simplex virus. Various oncolytic viruses from diverse viral families have advanced into clinical studies. The promise of OVs is that they offer direct tumor cell killing as well as immune stimulation, making them ideal combination partners for immuno-oncology agents such as checkpoint inhibitors. Newcastle disease virus (NDV) is a negative-strand RNA virus from the family paramyxoviridae that causes disease in avian species (the natural host). The anticancer potential of a mesogenic strain of NDV has been investigated in several clinical studies with mixed success. Since it was classified as a select agent because of its pathogenicity in chickens, the clinical development of NDV as an oncolytic agent has been challenging. MEDI5395 is a recombinant strain of NDV which has been engineered to express granulocyte/ macrophage colony-stimulating factor (GM-CSF). The nonclinical safety assessment strategy employed, including study design challenges, regulatory requirements, and critical study endpoints such as biodistribution, transgene expression, and shedding, will be described.
Part 2: Case Studies for the Development of Specialty Biotherapeutics
The aim of the presentation will be to present a number of case studies for different types of immuno-oncology drugs, including T cell engagers, immunostimulatory antibody-drug conjugates (ISACs), protein-based cancer vaccines and immunostimulatory adjuvants, and mRNA-based immunomodulators. These case studies will highlight some of the key challenges in the non-clinical safety assessment of these molecules and entry into the clinic. Topics covered will include candidate design and optimization to minimize adverse safety events/immunogenicity, in vitro safety studies with human cells, assessing potential for off-tumor/on-target and off-target binding, species selection and qualification for in vivo pharmacology and toxicology studies, design of Dose Range-Finding (DRF) and IND-enabling GLP toxicity studies and inclusion of PK, PD, and safety endpoints, immunogenicity assessment, and First-In-Human (FIH) dose selection (balancing the risk-benefit to cancer patients and so not starting too low). Regulatory expectations will also be highlighted.
$i++ ?>Michelle Coulson, PhD, ERT
Toxicology Project Leader
Novartis
Dr. Michelle Coulson earned her PhD in Molecular Toxicology from the University of Surrey, UK. She is currently a Toxicology Project Leader in the Department of Preclinical Safety at Novartis Institutes for Biomedical Research in Cambridge, Massachusetts. She has over 19 years of experience in preclinical safety assessment in the pharmaceutical industry supporting a diverse range of small molecules, monoclonal antibodies, bi-/tri-specific antibodies and antibody-drug conjugates. Dr. Coulson holds a board certification from the ERT.
$i++ ?>Patricia Ryan, PhD
Senior Director, Clinical Pharmacology and Safety Sciences
AstraZeneca
Dr. Patricia Ryan has over 30 years of experience in the biopharmaceutical industry with an emphasis on nonclinical safety testing of biologics and vaccines. Currently, she is the Strategic Toxicology Lead for Infectious Diseases at AstraZeneca and leads nonclinical safety strategy for this therapy area in Safety Sciences. Before that, she directed toxicology in Biologics Safety Assessment at MedImmune.
Dr. Ryan is currently President of the American College of Toxicology. She has been an active member of ACT since 2004. She was elected to the Education Committee in 2008 and to Council in 2012. While on Council, she chaired the Education Committee. She served as ACT Secretary from 2021–2022. She has served on the Program Committee multiple times. She is also a member of the Society of Toxicology and represents AZ on the IQ Consortium DruSafe Leadership Group.
Dr. Ryan obtained her bachelor’s degree in chemistry from the University of Virginia and her PhD in chemistry from Johns Hopkins University. She trained as a postdoctoral scientist at SmithKline Beecham (now GlaxoSmithKline).
Registration Fees:
Seminar registration is restricted to single person use only. Please note that all eLearning sales are final. No cancellations or refunds will be allotted after payment is processed.
| Registration Type | Set/Module 1–4 |
| ACT Member | $225 |
| ACT Student/Transitional/Postdoctoral Researcher Member | $125 |
| Nonmember | $350 |
*Fees are assessed according to membership status at the time of purchase. There are no exceptions and no refunds after payment has been processed.
The Specialty Oncology Biotherapeutics eLearning seminar content will only be available until December 31, 2027.